Clovis Oncology Inc. Stock
Clovis Oncology Inc. gained 1.800% today.
The community is currently still undecided about Clovis Oncology Inc. with 1 Buy predictions and 0 Sell predictions.
So far the community has only identified positive things for Clovis Oncology Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Clovis Oncology Inc. in the next few years
Pros
2
Could be worthwhile Investment >10% per year
1
Small cyclical dependencies
1
Known brand
Cons
0
-
Performance of Clovis Oncology Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Clovis Oncology Inc. | 1.800% | -4.692% | -25.628% | -32.320% | -23.649% | -81.533% | -91.766% |
| Champions Oncology Inc | 3.870% | -13.636% | -9.524% | -15.556% | -16.022% | - | - |
| Aveo Pharmaceuticals Inc. | -1.250% | -1.852% | -5.438% | 25.056% | 24.636% | -69.590% | -9.365% |
| Epizyme Inc. | -3.170% | -6.869% | -23.779% | -75.103% | -70.073% | - | - |
Comments
Other discussions about Clovis Oncology Inc. Stock
New thread ForumNews
Clovis Oncology Announces Third Quarter 2021 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2021, and provided an update on the Company’s clinical development programs and regulatory and
Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2021 financial results on Wednesday, November 3, 2021, before the open of the US financial markets. Clovis’ senior management
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
Clovis Oncology, Inc. (NASDAQ: CLVS) and ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, today announced the signing of a clinical supply agreement that provides